A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and...
-
Upload
sherman-elliott -
Category
Documents
-
view
214 -
download
0
Transcript of A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and...
![Page 1: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/1.jpg)
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone in Recurrent Platinum-sensitive Ovarian Cancer
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 2: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/2.jpg)
Background: cediranib and olaparib are active agents in ovarian cancer
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 3: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/3.jpg)
Cediranib and olaparib have synergistic activity in vitro
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 4: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/4.jpg)
Phase 1 study of cediranib and olaparib demonstrated activity in ovarian cancer patients
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 5: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/5.jpg)
Study Objectives
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 6: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/6.jpg)
Study Design
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 7: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/7.jpg)
Key eligibility criteria
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 8: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/8.jpg)
Statistical Considerations
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 9: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/9.jpg)
Study Status and Data Analysis
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 10: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/10.jpg)
Patient Characteristics
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 11: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/11.jpg)
Primary Outcome: Cediranib/olaparib significantly increased PFS compared to olaparib alone
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 12: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/12.jpg)
Secondary Outcome: Cediranib/olaparib significantly increased overall response rate (ORR) compared to olaparib alone
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 13: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/13.jpg)
Cediranib/olaparib significantly increased PFS in patients without a BRCA mutation
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 14: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/14.jpg)
Treatment-related Adverse Events
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 15: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/15.jpg)
Tolerability of cediranib/olaparib combination
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 16: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/16.jpg)
Conclusions
Presented By Joyce Liu at 2014 ASCO Annual Meeting
![Page 17: A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.](https://reader030.fdocuments.in/reader030/viewer/2022032702/56649f435503460f94c63975/html5/thumbnails/17.jpg)
Acknowledgments
Presented By Joyce Liu at 2014 ASCO Annual Meeting